Literature DB >> 10878400

Left ventricular hypertrophy in hypertensive patients with autosomal dominant polycystic kidney disease: influence of blood pressure and humoral and neurohormonal factors.

A Martinez-Vea1, F A Valero, A Bardaji, C Gutierrez, M Broch, C Garcia, C Richart, J A Oliver.   

Abstract

Left ventricular hypertrophy (LVH) is a common finding in hypertensive autosomal dominant polycystic kidney disease (ADPKD) patients. There are few studies on the influence of blood pressure (BP) and nonhemodynamic factors on LVH in these patients. The aim of this study was to evaluate the relationship between BP, humoral and neurohormonal factors and left ventricular mass (LVM) in hypertensive ADPKD patients. In 20 hypertensive ADPKD patients, ambulatory BP was monitored for 24 h, left ventricular dimensions were estimated by echocardiography, and plasma renin activity (PRA), plasma noradrenaline (NA), angiotensin II (Ang II), aldosterone, atrial natriuretic peptide (ANP) and insulin-like growth factor I (IGF-I) were also determined. Twenty age- and sex-matched essential hypertensive subjects served as controls. Ambulatory BP and LVM index were similar in the two groups, although male ADPKD patients had higher LVM indices than their matched controls. Eight ADPKD patients (40%) and 6 essential hypertensives (30%) showed LVH. PRA, Ang II, aldosterone, ANP and IGF-I levels were similar in the two groups, but plasma NA levels were higher in ADPKD patients than in controls (281 +/- 158 vs. 160 +/- 62 pg/ml, p = 0.004). ADPKD patients with LVH did not differ from those without LVH with regard to humoral and neurohormonal parameters, but had higher ambulatory BP levels. In ADPKD patients, correlation analysis revealed a significant association between LVM index and 24-hour systolic and diastolic BP, but not with any of the hormonal factors evaluated. On multiple regression analysis, 24-hour diastolic BP was the only independent variable linked to LVM index. In conclusion, ambulatory BP is one of the most important determinants of LVM in hypertensive ADPKD patients. Further studies are warranted to elucidate the role of nonhemodynamic factors in the pathogenesis of LVH in this population. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10878400     DOI: 10.1159/000013583

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  13 in total

1.  Decreased polycystin 2 expression alters calcium-contraction coupling and changes β-adrenergic signaling pathways.

Authors:  Ivana Y Kuo; Andrea T Kwaczala; Lily Nguyen; Kerry S Russell; Stuart G Campbell; Barbara E Ehrlich
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

Review 2.  Hypertension in autosomal dominant polycystic kidney disease.

Authors:  Arlene B Chapman; Konrad Stepniakowski; Frederic Rahbari-Oskoui
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

Review 3.  Predictors of autosomal dominant polycystic kidney disease progression.

Authors:  Robert W Schrier; Godela Brosnahan; Melissa A Cadnapaphornchai; Michel Chonchol; Keith Friend; Berenice Gitomer; Sandro Rossetti
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

4.  Epicardial Fat Thickness in Patients with Autosomal Dominant Polycystic Kidney Disease.

Authors:  Antonio Concistrè; Luigi Petramala; Gianmarco Scoccia; Susanna Sciomer; Valeria Bisogni; Vincenza Saracino; Gino Iannucci; Silvia Lai; Daniela Mastroluca; Gianluca Iacobellis; Claudio Letizia
Journal:  Cardiorenal Med       Date:  2018-05-03       Impact factor: 2.041

5.  A young patient with a family history of hypertension.

Authors:  Aldo J Peixoto
Journal:  Clin J Am Soc Nephrol       Date:  2014-08-04       Impact factor: 8.237

6.  Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: from impaired tubules to impaired carotid and coronary arteries.

Authors:  Kultigin Turkmen; Huseyin Oflaz; Bora Uslu; Arif O Cimen; Ali Elitok; Erdem Kasikcioglu; Sabahat Alisir; Fatih Tufan; Sule Namli; Mukremin Uysal; Tevfik Ecder
Journal:  Clin J Am Soc Nephrol       Date:  2008-03-19       Impact factor: 8.237

7.  Polycystin 2-dependent cardio-protective mechanisms revealed by cardiac stress.

Authors:  Esther Giehl; Fernanda O Lemos; Yan Huang; Frank J Giordano; Ivana Y Kuo; Barbara E Ehrlich
Journal:  Pflugers Arch       Date:  2017-07-31       Impact factor: 3.657

8.  Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression?

Authors:  Asmin Andries; Kristien Daenen; François Jouret; Bert Bammens; Djalila Mekahli; Ann Van Schepdael
Journal:  Pediatr Nephrol       Date:  2018-08-13       Impact factor: 3.714

9.  ADPKD: Prototype of Cardiorenal Syndrome Type 4.

Authors:  Grazia Maria Virzì; Valentina Corradi; Anthi Panagiotou; Fiorella Gastaldon; Dinna N Cruz; Massimo de Cal; Maurizio Clementi; Claudio Ronco
Journal:  Int J Nephrol       Date:  2010-12-21

10.  Developments in the management of autosomal dominant polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Mir Reza Bekheirnia; Robert W Schrier
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.